Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Mallinckrodt
Colorcon
Express Scripts
Merck

Last Updated: December 7, 2022

Details for Patent: 8,460,704


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 8,460,704
Title:Extended release formulation of nevirapine
Abstract: The invention relates to an extended release pharmaceutical composition comprising nevirapine.
Inventor(s): Cappola; Michael L. (Malvern, PA), Sienkiewicz; Svetlana (New Milford, CT), Snow; Glenn Charles (Sandy Hook, CT), Chen; Feng-Jing (Danbury, CT)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:12/523,226
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 8,460,704

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Boehringer Ingelheim VIRAMUNE XR nevirapine TABLET, EXTENDED RELEASE;ORAL 201152-001 Mar 25, 2011 AB RX Yes Yes See Plans and Pricing See Plans and Pricing TREATMENT OF HIV-1 BY ONCE DAILY ADMINISTRATION See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,460,704

PCT Information
PCT FiledJune 04, 2008PCT Application Number:PCT/US2008/065705
PCT Publication Date:December 18, 2008PCT Publication Number: WO2008/154234

International Family Members for US Patent 8,460,704

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 066924 See Plans and Pricing
Australia 2008262031 See Plans and Pricing
Brazil PI0811732 See Plans and Pricing
Canada 2687491 See Plans and Pricing
Chile 2008001678 See Plans and Pricing
China 101784263 See Plans and Pricing
Colombia 6150128 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Moodys
McKesson
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.